Interval post-colonoscopy colorectal cancer following a negative colonoscopy in a fecal immunochemical test-based screening program.

Autor:	van de Schootbrugge-Vandermeer HJ; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Kooyker AI; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Wisse PHA; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Nagtegaal ID; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands., Geuzinge HA; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Toes-Zoutendijk E; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands., de Jonge L; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Breekveldt ECH; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands.; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Vuuren AJ; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., van Kemenade FJ; Department of Pathology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Ramakers CRB; Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Dekker E; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC, Amsterdam, The Netherlands., Lansdorp-Vogelaar I; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Spaander MCW; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., van Leerdam ME; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
Jazyk:	angličtina
Zdroj:	Endoscopy [Endoscopy] 2023 Dec; Vol. 55 (12), pp. 1061-1069. Date of Electronic Publication: 2023 Oct 04.
DOI:	10.1055/a-2136-6564
Abstrakt:	Background:  In the Dutch colorectal (CRC) screening program, fecal immunochemical test (FIT)-positive individuals are referred for colonoscopy. If no relevant findings are detected at colonoscopy, individuals are reinvited for FIT screening after 10 years. We aimed to assess CRC risk after a negative colonoscopy in FIT-positive individuals. Methods:  In this cross-sectional cohort study, data were extracted from the Dutch national screening information system. Participants with a positive FIT followed by a negative colonoscopy between 2014 and 2018 were included. A negative colonoscopy was defined as a colonoscopy during which no more than one nonvillous, nonproximal adenoma < 10 mm or serrated polyp < 10 mm was found. The main outcome was interval post-colonoscopy CRC (iPCCRC) risk. iPCCRC risk was reviewed against the risk of interval CRC after a negative FIT (FIT IC) with a 2-year screening interval. Results:  35 052 FIT-positive participants had a negative colonoscopy and 24 iPCCRCs were diagnosed, resulting in an iPCCRC risk of 6.85 (95 %CI 4.60-10.19) per 10 000 individuals after a median follow-up of 1.4 years. After 2.5 years of follow-up, age-adjusted iPCCRC risk was approximately equal to FIT IC risk at 2 years. Conclusion:  Risk of iPCCRC within a FIT-based CRC screening program was low during the first years after colonos-copy but, after 2.5 years, was the same as the risk in FIT-negative individuals at 2 years, when they are reinvited for screening. Colonoscopy quality may therefore require further improvement and FIT screening interval may need to be reduced after negative colonoscopy. Competing Interests: E. Dekker has received endoscopic equipment on loan from Olympus and FujiFilm, and research grant from FujiFilm; she has also received honoraria for consultancy from FujiFilm, Tillots, Olympus, GI Supply, Cancer Prevention Pharmaceuticals, PAION, and Ambu, and speakers’ fees from Olympus, Roche, GI Supply, PAION, and IPSEN. I. Lansdorp-Vogelaar is an associate editor for Gastroenterology, expert at the Health Council, panel member of the European Commission Initiative on Colorectal Cancer, and visiting scientist at the International Agency for Research on Cancer. M.C.W. Spaander has received research support from Sentinel, Sysmex, Boston Scientific, Norgine, and Medtronic. H.J. van de Schootbrugge-Vandermeer, A.I. Kooyker, P.H.A. Wisse, I.D. Nagtegaal, H.A. Geuzinge, E. Toes-Zoutendijk, L. de Jonge, E.C.H. Breekveldt, A.J. van Vuuren, F.J. van Kemenade, C.R.B. Ramakers, and M.E. van Leerdam declare that they have no conflict of interest. (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu